Diversified science and technology company Danaher (NYSE:DHR) beat Wall Street’s revenue expectations in Q3 CY2025, with ...

Discover Danaher's strong Q3 results, strategic reinvestments, and biotech growth. See why DHR is poised for future earnings ...

Danaher stock surged over 7% on Tuesday after the company delivered a solid third-quarter performance, with revenues rising 4.5% to $6.1 billion and non-GAAP adjusted EPS of $1.89, significantly ...

It is financial reporting season, and a few major medtech companies posted third-quarter sales growth. | It is financial ...

Danaher Corporation ( NYSE: DHR) Q3 2025 Earnings Call October 21, 2025 8:00 AM EDT ...

The expansion of the HSV testing market is being fueled by a combination of increasing prevalence of HSV infections, ...

The firm hopes to exploit its first-mover advantage in the OTC space following de novo clearance for an at-home PCR test to detect sexually transmitted infections.

Danaher Corp (DHR) reports robust Q3 performance with $6.1 billion in sales, a 10% increase in adjusted EPS, and a $2 billion ...

"Cepheids don't pulse at the same rate, but rather at a rate proportional to their brightness, which means that from an ...

"Cepheids don't pulse at the same rate, but rather at a rate proportional to their brightness, which means that from an ...